Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: A 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochloride
- 27 October 2011
- journal article
- research article
- Published by Wiley in Nephrology
- Vol. 16 (8) , 743-750
Abstract
Aim: SBR759 is a calcium‐free, polymeric, iron(III)‐based oral phosphate binder, in development for the treatment of hyperphosphatemia. The efficacy and safety of SBR759 was compared with sevelamer hydrochloride in chronic kidney dialysis patients on hemodialysis.Methods: Japanese and Taiwanese hyperphosphatemic patients who were on hemodialysis (n = 203) received starting doses of 3.0 or 4.5 g/day SBR759 or 2.4 or 4.8 g/day sevelamer‐hydrochloride (HCl) based on baseline phosphate levels. Daily doses were up‐titrated every 2 weeks to reach the Kidney Disease Outcomes Quality Initiative (K/DOQI) recommended target serum phosphate concentration ≤1.7 mmol/L. The key endpoints were proportion of patients achieving target serum phosphate and the safety at week 12.Results: SBR759 showed a superior phosphate response at week 12 compared with sevelamer‐HCl (83% vs 54% patients; P < 0.0001). Mean serum calcium concentrations were unaffected by either treatment. Similar incidences of adverse events and serious adverse events were seen with SBR759 and sevelamer‐HCl (90.3% vs 94.1% and 5.2% vs 4.4%, respectively), but overall discontinuation rates were lower with SBR759 (11.9% vs 20.6%). The proportion of patients experiencing gastrointestinal disorders was lower in SBR759 versus sevelamer‐HCl. No treatment‐related serious adverse events were reported.Conclusions: SBR759 showed superior phosphate control with a favorable tolerability profile compared to sevelamer‐HCl in hemodialysis patients.Keywords
This publication has 17 references indexed in Scilit:
- Efficacy and safety of SBR759, a new iron-based phosphate binderKidney International, 2010
- Tissue Accumulation of Lanthanum as Compared to Aluminum in Rats with Chronic Renal Failure – Possible Harmful Effects after Long-Term ExposureNephron Experimental Nephrology, 2010
- Oral Phosphate Binders in Patients with Kidney FailureNew England Journal of Medicine, 2010
- Ten-Year Experience with Sevelamer and Calcium Salts as Phosphate BindersClinical Journal of the American Society of Nephrology, 2010
- ORAL PHOSPHATE BINDERS FOR THE MANAGEMENT OF SERUM PHOSPHATE LEVELS IN DIALYSIS PATIENTSJournal of Renal Care, 2009
- Systematic review of the clinical efficacy and safety of sevelamer in dialysis patientsNephrology Dialysis Transplantation, 2007
- K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?International Urology and Nephrology, 2006
- Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2004
- Arterial stiffening and vascular calcifications in end‐stage renal diseaseNephrology Dialysis Transplantation, 2000
- Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing DialysisNew England Journal of Medicine, 2000